Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07683975 · ClinicalTrials.gov registry record · Phase 4
Infliximab for Immune Checkpoint Inhibitor Associated AKI
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT07683975: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT07683975 is a Phase 4 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07683975, a Phase 4 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a multi-center, 1:1 randomized pilot study examining the efficacy and safety of infliximab 5mg/kg x 1 paired with 2 weeks of prednisone 1mg/kg per day for 2 weeks versus standard-of-care glucocorticoid therapy (prednisone 1mg/kg/day x 2 weeks followed by a 4 week taper) on the rate and speed of renal recovery from immune checkpoint inhibitor-associated AKI.
Interventions
- DRUG Prednisone
- DRUG Infliximab
- DRUG prednisone (oral)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-07-16 |
| Est. Completion | 2029-07-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07683975
The ClinicalTrials.gov registry entry for NCT07683975 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT07683975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07683975 about?
NCT07683975 is a clinical study titled "Infliximab for Immune Checkpoint Inhibitor Associated AKI". This is a multi-center, 1:1 randomized pilot study examining the efficacy and safety of infliximab 5mg/kg x 1 paired with 2 weeks of prednisone 1mg/kg per day for 2 weeks versus standard-of-care glucocorticoid therapy (prednisone 1mg/kg/day x 2 weeks followed by a 4 week taper) on the rate and speed...
What is the current status of trial NCT07683975?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2026-07-16. Estimated completion is 2029-07-16.
What interventions are being tested in trial NCT07683975?
The interventions under investigation include: Prednisone (DRUG), Infliximab (DRUG), prednisone (oral) (DRUG).
Who is sponsoring clinical trial NCT07683975?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.